100 related articles for article (PubMed ID: 29972300)
1. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
2. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
3. Structural studies of intrinsically disordered MLL-fusion protein AF9 in complex with peptidomimetic inhibitors.
Yang Y; Ahmad E; Premkumar V; Liu A; Ashikur Rahman SM; Nikolovska-Coleska Z
Protein Sci; 2024 Jun; 33(6):e5019. PubMed ID: 38747396
[TBL] [Abstract][Full Text] [Related]
4. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia.
Itskovich SS; Gurunathan A; Clark J; Burwinkel M; Wunderlich M; Berger MR; Kulkarni A; Chetal K; Venkatasubramanian M; Salomonis N; Kumar AR; Lee LH
Nat Commun; 2020 May; 11(1):2369. PubMed ID: 32398749
[TBL] [Abstract][Full Text] [Related]
5. DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding.
Spangler CJ; Yadav SP; Li D; Geil CN; Smith CB; Wang GG; Lee TH; McGinty RK
Cell Rep; 2022 Feb; 38(7):110369. PubMed ID: 35172132
[TBL] [Abstract][Full Text] [Related]
6. The PHD fingers of MLL block MLL fusion protein-mediated transformation.
Muntean AG; Giannola D; Udager AM; Hess JL
Blood; 2008 Dec; 112(12):4690-3. PubMed ID: 18796627
[TBL] [Abstract][Full Text] [Related]
7. Installation of a cancer promoting WNT/SIX1 signaling axis by the oncofusion protein MLL-AF9.
Zhang LS; Kang X; Lu J; Zhang Y; Wu X; Wu G; Zheng J; Tuladhar R; Shi H; Wang Q; Morlock L; Yao H; Huang LJ; Maire P; Kim J; Williams N; Xu J; Chen C; Zhang CC; Lum L
EBioMedicine; 2019 Jan; 39():145-158. PubMed ID: 30528456
[TBL] [Abstract][Full Text] [Related]
8. DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.
Godfrey L; Crump NT; Thorne R; Lau IJ; Repapi E; Dimou D; Smith AL; Harman JR; Telenius JM; Oudelaar AM; Downes DJ; Vyas P; Hughes JR; Milne TA
Nat Commun; 2019 Jun; 10(1):2803. PubMed ID: 31243293
[TBL] [Abstract][Full Text] [Related]
9. HOXA9 promotes MYC-mediated leukemogenesis by maintaining gene expression for multiple anti-apoptotic pathways.
Miyamoto R; Kanai A; Okuda H; Komata Y; Takahashi S; Matsui H; Inaba T; Yokoyama A
Elife; 2021 Jul; 10():. PubMed ID: 34310280
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of DOT1L in cell proliferation and differentiation: Friend or foe.
Wu D; Zhang J; Jun Y; Liu L; Huang C; Wang W; Yang C; Xiang Z; Wu J; Huang Y; Meng D; Yang Z; Zhou X; Cheng C; Yang J
Histol Histopathol; 2024 Apr; 39(4):425-435. PubMed ID: 37706592
[TBL] [Abstract][Full Text] [Related]
11. The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia.
Wang G; Zhang W; Ren J; Zeng Y; Dang X; Tian X; Yu W; Li Z; Ma Y; Yang P; Lu J; Zheng J; Lu B; Xu J; Liang A
Oncogene; 2024 Apr; ():. PubMed ID: 38671157
[TBL] [Abstract][Full Text] [Related]
12. Polyamine-based small molecule epigenetic modulators.
Sharma SK; Hazeldine S; Crowley ML; Hanson A; Beattie R; Varghese S; Senanayake TM; Hirata A; Hirata F; Huang Y; Wu Y; Steinbergs N; Murray-Stewart T; Bytheway I; Casero RA; Woster PM
Medchemcomm; 2012; 3(1):14-21. PubMed ID: 23293738
[TBL] [Abstract][Full Text] [Related]
13. Oxidative Stress-Mediated RUNX3 Mislocalization Occurs Via Jun Activation Domain-Binding Protein 1 and Histone Modification.
Kang KA; Piao MJ; Fernando PDSM; Herath HMUL; Boo HJ; Yoon SP; Hyun JW
Appl Biochem Biotechnol; 2024 Apr; ():. PubMed ID: 38683453
[TBL] [Abstract][Full Text] [Related]
14. Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia.
Zee BM; Poels KE; Yao CH; Kawabata KC; Wu G; Duy C; Jacobus WD; Senior E; Endress JE; Jambhekar A; Lovitch SB; Ma J; Dhall A; Harris IS; Blanco MA; Sykes DB; Licht JD; Weinstock DM; Melnick A; Haigis MC; Michor F; Shi Y
iScience; 2021 Jun; 24(6):102651. PubMed ID: 34151238
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
[TBL] [Abstract][Full Text] [Related]
16. Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases.
Vega-García N; Malatesta R; Estella C; Pérez-Jaume S; Esperanza-Cebollada E; Torrebadell M; Català A; Gassiot S; Berrueco R; Ruiz-Llobet A; Alonso-Saladrigues A; Mesegué M; Pont-Martí S; Rives S; Camós M
Br J Haematol; 2018 Aug; 182(4):542-553. PubMed ID: 29978456
[TBL] [Abstract][Full Text] [Related]
17. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia.
Magliulo D; Bernardi R; Messina S
Front Oncol; 2018; 8():255. PubMed ID: 30073149
[TBL] [Abstract][Full Text] [Related]
18. Region-specific alteration of histone modification by LSD1 inhibitor conjugated with pyrrole-imidazole polyamide.
Alagarswamy K; Shinohara KI; Takayanagi S; Fukuyo M; Okabe A; Rahmutulla B; Yoda N; Qin R; Shiga N; Sugiura M; Sato H; Kita K; Suzuki T; Nemoto T; Kaneda A
Oncotarget; 2018 Jun; 9(50):29316-29335. PubMed ID: 30034620
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
20. Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.
Cai SF; Chu SH; Goldberg AD; Parvin S; Koche RP; Glass JL; Stein EM; Tallman MS; Sen F; Famulare CA; Cusan M; Huang CH; Chen CW; Zou L; Cordner KB; DelGaudio NL; Durani V; Kini M; Rex M; Tian HS; Zuber J; Baslan T; Lowe SW; Rienhoff HY; Letai A; Levine RL; Armstrong SA
Cancer Discov; 2020 Oct; 10(10):1500-1513. PubMed ID: 32606137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
